Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — 9M 2015 Earnings Presentation
19 slides from Novo Nordisk A/s Class B's earnings presentation, Oct 29, 2015
Slide 1: Investor conference call First nine months of 2015
Slide 1 Investor conference call First nine months of 2015 Mexico City – part of Cities Changing Diabetes
Slide 2: Agenda
Investor conference call First nine months of 2015 Slide 2 Agenda Highlights and key events By Lars Rebien Sørensen, president and CEO Sales update By Lars Rebien Sørensen, president and CEO R&D update By Mads Krogsgaard Thomsen, CSO Financials and outlook By Jesper Brandgaard, CFO Questions and ans
Slide 3: Forward-looking statements
Investor conference call First nine months of 2015 Slide 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2014 and Form 20-F, both filed with the SEC in Febru
Slide 4: Highlights – first nine months of 2015
Investor conference call First nine months of 2015 Slide 4 Highlights – first nine months of 2015 Sales development • Sales increased by 23% in Danish kroner and 9% in local currencies • North America and International Operations grew by 33% and 23% in Danish kroner, respectively • Victoza® increase
Slide 5: North America is the main contributor to growth
Investor conference call First nine months of 2015 Slide 5 North America is the main contributor to growth Sales as reported – First nine months of 2015 Growth analysis – First nine months of 2015 Japan & Korea Local currencies Growth Share of growth Region China +10% North America 10% 56% +26% 5% 1
Slide 6: Growth is driven by Victoza and modern insulin
Investor conference call First nine months of 2015 Slide 6 Growth is driven by Victoza® and modern insulin Sales as reported – First nine months of 2015 Growth analysis – First nine months of 2015 Other biopharmaceuticals Local currencies Growth Share of growth Norditropin® +31% New-generation insul
Slide 7: Victoza maintains leadership in the faster growing US GLP-1 market
Investor conference call First nine months of 2015 Slide 7 Victoza® maintains leadership in the faster growing US GLP-1 market US GLP-1 market development US GLP-1 market shares MAT GLP-1 Growth rate Total TRx MAT volume GLP-1 TRx Victoza® exenatide TRx (000) growth rate market share albiglutide dul
Slide 8: North America drives strong Levemir growth despite increased competition
Investor conference call First nine months of 2015 Slide 8 North America drives strong Levemir® growth despite increased competition Levemir® sales growth driven by strong Levemir® gains US market share performance in North America despite introduction of glargine U300 DKK Growth in local currency N
Slide 9: Roll-out of degludec portfolio is progressing
Investor conference call First nine months of 2015 Slide 9 Roll-out of degludec portfolio is progressing Tresiba® value share of basal insulin segment Key launch observations in selected countries Switzerland India United Kingdom • Tresiba® launched in 36 countries Japan Sweden Germany • Tresiba® ha
Slide 10: Encouraging early prescription development for Saxenda
Investor conference call First nine months of 2015 Slide 10 Encouraging early prescription development for Saxenda® Prescription volume uptake of anti-obesity medications recently launched in the US Key launch observations TRx naltrexone HCI & bupropion HCI lorcaserin • Encouraging Saxenda® uptake c
Slide 11: Competitive US label for Tresiba
Investor conference call First nine months of 2015 Slide 11 Competitive US label for Tresiba® Tresiba® approved in the US for glycaemic control in adults with diabetes mellitus • Half-life of 25 hours and duration of action of at least 42 hours Profile • Day to day variability of 20% • Reduction in
Slide 12: Semaglutide shows superior HbA1c reduction and weight loss compared with exenatide in SUSTAIN 3
Investor conference call First nine months of 2015 Slide 12 Semaglutide shows superior HbA1c reduction and weight loss compared with exenatide once-weekly in SUSTAIN® 3 SUSTAIN® 3 trial design Headline results Semaglutide Exenatide 1.0 mg QW 2.0 mg QW Semaglutide 1.0 mg QW Change in HbA1c 813 people
Slide 13: Liraglutide label expansion in type 1 diabetes will not be pursued at present
Investor conference call First nine months of 2015 Slide 13 Based on assessment of ADJUNCT results, liraglutide label expansion in type 1 diabetes will not be pursued at present ADJUNCT ONE trial design Headline results • Greater improvement in HbA1c and statistically significantly greater weight re
Slide 14: Key development milestones
Investor conference call First nine months of 2015 Slide 14 Key development milestones • Xultophy® (IDegLira) filed with the US FDA for regulatory review • Faster-acting insulin aspart (NN1218) completed the planned additional 26-week treatment period of the onset® 1 trial Diabetes • Phase 3a develo
Slide 15: Financial results – first nine months of 2015
Investor conference call First nine months of 2015 Slide 15 Financial results – first nine months of 2015 DKK million 9M 2015 9M 2014 Change Sales 79,051 64,221 23% Gross profit 67,471 53,658 26% Gross margin 85.4% 83.6% Sales and distribution costs 20,273 16,544 23% Percentage of sales 25.6% 25.8%
Slide 16: Appreciation of key currencies against the Danish krone drives positive currency impact
Investor conference call First nine months of 2015 Slide 16 Appreciation of key currencies against the Danish krone drive significant positive currency impact in 2015 USD/DKK CNY/DKK JPY/DKK GBP/DKK CAD/DKK 135 Index (1 Jan 2014 = 100) Hedged 2014 2015 Spot Impact of a Hedging 130 Currencies average
Slide 17: Financial outlook for 2015
Investor conference call First nine months of 2015 Slide 17 Financial outlook for 2015 Expectations Previous expectations 29 October 2015 6 August 2015 Sales growth - local currencies 7-9% 7-9% Sales growth - reported Around 13 percentage points higher Around 14 percentage points higher Operating pr
Slide 18: Closing remarks
Investor conference call First nine months of 2015 Slide 18 Closing remarks Solid market performance Promising pipeline >≥10% annual diabetes care market growth driven •> • The only company with a full portfolio of novel by diabetes prevalence insulin products • 28% market share in diabetes care and
Slide 19: Investor contact information
Investor conference call First nine months of 2015 Slide 19 Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New